Atezolizumab is a new drug being tested in myeloma. It targets a protein called PDL-1 which is normally involved in dampening the immune response. This increases the activity of the immune system to recognize and destroy myeloma cells.

SparkCures ID 153
Developed By Genentech
Generic Name Atezolizumab
Additional Names MPDL3280A
Treatment Classifications
Treatment Targets

Clinical Trials


There are no resources, links or videos to display for this treatment.